SCHEDULE: ARK & Wood Boost Beam Therapeutics Stake to 10.35%
Beneficial Ownership Report
ARK Investment Management LLC and Catherine D. Wood have increased their beneficial ownership in Beam Therapeutics Inc. to 10.35% of common stock.
Summary
- ARK Investment Management LLC and Catherine D. Wood filed an Amendment No. 5 to their Schedule 13G.
- They collectively beneficially own 10,410,137 shares of Beam Therapeutics Inc. Common Stock.
- This represents 10.35% of the total class of securities.
- The filing indicates the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- ARK Innovation ETF, a series of a Delaware Statutory Trust, holds an interest exceeding 5% of the securities reported.
Sentiment
Score: 5
Explanation: This is a neutral filing, simply disclosing beneficial ownership. It does not inherently convey positive or negative sentiment about the company's performance or prospects, but a significant stake by a prominent investor like ARK could be seen as a positive signal by some.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- NA
Industry Context
NA
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Increased ownership by a prominent investment firm may signal confidence to existing and potential shareholders.
- No direct impact on employees, customers, suppliers, or creditors is indicated by this filing.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 07/31/2025 | Date of event requiring filing of this statement |
| 08/07/2025 | Signature date for ARK Investment Management LLC and Catherine D. Wood |
Keywords
Beam Therapeutics, ARK Investment Management, Catherine D. Wood, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Biotechnology Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.